Hikma Pharmaceuticals PLC
LSE:HIK

Watchlist Manager
Hikma Pharmaceuticals PLC Logo
Hikma Pharmaceuticals PLC
LSE:HIK
Watchlist
Price: 1 986 GBX 0.25% Market Closed
Market Cap: 4.4B GBX

Intrinsic Value

The intrinsic value of one HIK stock under the Base Case scenario is 4 789.83 GBX. Compared to the current market price of 1 986 GBX, Hikma Pharmaceuticals PLC is Undervalued by 59%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HIK Intrinsic Value
4 789.83 GBX
Undervaluation 59%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Hikma Pharmaceuticals PLC

Compare HIK to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about HIK?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Hikma Pharmaceuticals PLC
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Hikma Pharmaceuticals PLC

Current Assets 2.3B
Cash & Short-Term Investments 213m
Receivables 973m
Other Current Assets 1.1B
Non-Current Assets 2.9B
Long-Term Investments 62m
PP&E 1.3B
Intangibles 1.2B
Other Non-Current Assets 326m
Efficiency

Free Cash Flow Analysis
Hikma Pharmaceuticals PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Hikma Pharmaceuticals PLC

Revenue
3.2B USD
Cost of Revenue
-1.7B USD
Gross Profit
1.4B USD
Operating Expenses
-819m USD
Operating Income
629m USD
Other Expenses
-270m USD
Net Income
359m USD
Fundamental Scores

HIK Profitability Score
Profitability Due Diligence

Hikma Pharmaceuticals PLC's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin
Healthy Operating Margin
Sustainable 3Y Average Gross Margin
Positive ROE
54/100
Profitability
Score

Hikma Pharmaceuticals PLC's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

HIK Solvency Score
Solvency Due Diligence

Hikma Pharmaceuticals PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Average Altman Z-Score
Short-Term Solvency
51/100
Solvency
Score

Hikma Pharmaceuticals PLC's solvency score is 51/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HIK Price Targets Summary
Hikma Pharmaceuticals PLC

Wall Street analysts forecast HIK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HIK is 2 562.52 GBX with a low forecast of 2 121 GBX and a high forecast of 3 255 GBX.

Lowest
Price Target
2 121 GBX
7% Upside
Average
Price Target
2 562.52 GBX
29% Upside
Highest
Price Target
3 255 GBX
64% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for HIK is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

HIK Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one HIK stock?

The intrinsic value of one HIK stock under the Base Case scenario is 4 789.83 GBX.

Is HIK stock undervalued or overvalued?

Compared to the current market price of 1 986 GBX, Hikma Pharmaceuticals PLC is Undervalued by 59%.

Back to Top